WO2006135978A1 - Antiviral compounds and methods - Google Patents
Antiviral compounds and methods Download PDFInfo
- Publication number
- WO2006135978A1 WO2006135978A1 PCT/AU2006/000880 AU2006000880W WO2006135978A1 WO 2006135978 A1 WO2006135978 A1 WO 2006135978A1 AU 2006000880 W AU2006000880 W AU 2006000880W WO 2006135978 A1 WO2006135978 A1 WO 2006135978A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- guanidine
- napthoyl
- virus
- compound
- phenyl
- Prior art date
Links
- 0 N*(NC(CCc1c(CCC2)c2ccc1)=O)=N Chemical compound N*(NC(CCc1c(CCC2)c2ccc1)=O)=N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020087001886A KR101419327B1 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
EP06741271.8A EP1902017B1 (en) | 2005-06-24 | 2006-06-23 | Antiviral acylguanidine compounds |
AU2006261593A AU2006261593B2 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
DK06741271.8T DK1902017T3 (en) | 2005-06-24 | 2006-06-23 | Antiviral acylguanidine compounds |
EP13197255.6A EP2826770B1 (en) | 2005-06-24 | 2006-06-23 | Acylguanidine compounds with antiviral activity |
NZ564398A NZ564398A (en) | 2005-06-24 | 2006-06-23 | 2-Naphthoyl-guanidine derivatives as antiviral agents |
CA2612403A CA2612403C (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
ES06741271.8T ES2491217T3 (en) | 2005-06-24 | 2006-06-23 | Antiviral acylguanidine compounds |
PL06741271T PL1902017T3 (en) | 2005-06-24 | 2006-06-23 | Antiviral acylguanidine compounds |
CN2006800226410A CN101208297B (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
US11/922,281 US8669280B2 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
KR1020147010199A KR20140072101A (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
BR122020006906A BR122020006906B8 (en) | 2005-06-24 | 2006-06-23 | antiviral compounds and pharmaceutical compositions |
BRPI0612309A BRPI0612309B8 (en) | 2005-06-24 | 2006-06-23 | antiviral compounds and pharmaceutical compositions |
PL13197255T PL2826770T3 (en) | 2005-06-24 | 2006-06-23 | Acylguanidine compounds with antiviral activity |
JP2008517277A JP5373392B2 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
HK08104365.1A HK1109615A1 (en) | 2005-06-24 | 2008-04-17 | Antiviral acylguanidine compounds |
US14/071,870 US9440926B2 (en) | 2005-06-24 | 2013-11-05 | Antiviral compounds and methods |
US15/262,075 US10683263B2 (en) | 2005-06-24 | 2016-09-12 | Antiviral compounds and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005903360A AU2005903360A0 (en) | 2005-06-24 | Anti-viral compounds and methods | |
AU2005903360 | 2005-06-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/922,281 A-371-Of-International US8669280B2 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
US14/071,870 Division US9440926B2 (en) | 2005-06-24 | 2013-11-05 | Antiviral compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006135978A1 true WO2006135978A1 (en) | 2006-12-28 |
Family
ID=37570036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2006/000880 WO2006135978A1 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
Country Status (17)
Country | Link |
---|---|
US (3) | US8669280B2 (en) |
EP (2) | EP1902017B1 (en) |
JP (2) | JP5373392B2 (en) |
KR (2) | KR20140072101A (en) |
CN (2) | CN103274970B (en) |
AU (1) | AU2006261593B2 (en) |
BR (2) | BRPI0612309B8 (en) |
CA (1) | CA2612403C (en) |
DK (2) | DK1902017T3 (en) |
ES (2) | ES2491217T3 (en) |
HK (2) | HK1109615A1 (en) |
NZ (3) | NZ596107A (en) |
PL (2) | PL1902017T3 (en) |
PT (2) | PT2826770T (en) |
SG (1) | SG163517A1 (en) |
WO (1) | WO2006135978A1 (en) |
ZA (1) | ZA200800256B (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147962A1 (en) * | 2007-05-23 | 2008-12-04 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
WO2009018609A1 (en) * | 2007-08-03 | 2009-02-12 | Biotrom Limited | Hepatitis c antiviral compositions and methods |
WO2011016504A1 (en) | 2009-08-06 | 2011-02-10 | アステラス製薬株式会社 | Nitrogenous-ring acylguanidine derivative |
EP2394987A1 (en) * | 2009-02-09 | 2011-12-14 | Astellas Pharma Inc. | Acylguanidine derivative |
EP2394988A1 (en) * | 2009-02-09 | 2011-12-14 | Astellas Pharma Inc. | Substituted acylguanidine derivative |
AU2013219202B2 (en) * | 2007-08-03 | 2016-12-08 | Biotron Limited | Hepatitis C antiviral compositions and methods |
US11007208B2 (en) | 2015-09-16 | 2021-05-18 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
WO2021102508A1 (en) * | 2019-11-26 | 2021-06-03 | Biotron Limited | Methods of treating hiv-1 infection |
WO2021154687A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
WO2021262826A2 (en) | 2020-06-24 | 2021-12-30 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
US11260070B2 (en) | 2017-03-14 | 2022-03-01 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2022046631A1 (en) | 2020-08-24 | 2022-03-03 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
US11266681B2 (en) | 2017-07-11 | 2022-03-08 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
US11266666B2 (en) | 2014-10-29 | 2022-03-08 | Gilead Sciences, Inc. | Methods for treating Filoviridae virus infections |
WO2022081973A1 (en) | 2020-10-16 | 2022-04-21 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
US11491169B2 (en) | 2020-05-29 | 2022-11-08 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11492353B2 (en) | 2010-07-22 | 2022-11-08 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
WO2022251318A1 (en) | 2021-05-26 | 2022-12-01 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
US11597742B2 (en) | 2017-05-01 | 2023-03-07 | Gilead Sciences, Inc. | Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate |
US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
WO2023092180A1 (en) * | 2021-11-24 | 2023-06-01 | Biotron Limited | Methods of treating sars-cov-2 infection |
WO2023168254A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
WO2023167938A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023168194A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023239665A1 (en) | 2022-06-06 | 2023-12-14 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
WO2024006461A1 (en) | 2022-06-30 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112687A2 (en) * | 2003-06-26 | 2004-12-29 | Biotron Limited | Antiviral acylguanidine compounds and methods |
DK1902017T3 (en) * | 2005-06-24 | 2014-06-30 | Biotron Ltd | Antiviral acylguanidine compounds |
EP2177505A4 (en) * | 2007-08-10 | 2011-08-31 | Astellas Pharma Inc | Bicyclic acylguanidine derivative |
US9126106B1 (en) | 2010-11-05 | 2015-09-08 | Wms Gaming, Inc. | Promotional content coordination in wagering game machines |
MX2013006951A (en) * | 2010-12-16 | 2013-10-03 | Abbvie Inc | Anti-viral compounds. |
KR102607599B1 (en) * | 2017-02-08 | 2023-11-28 | 바이오트론 리미티드 | How to treat influenza |
WO2023167055A1 (en) * | 2022-03-03 | 2023-09-07 | 日本曹達株式会社 | Antiviral agent |
CN115260100B (en) * | 2022-08-08 | 2023-12-12 | 赛诺瑞生物医药技术(无锡)有限公司 | Substituted acyl guanidine compound for preparing coronavirus therapeutic drug and application |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4251545A (en) | 1979-09-19 | 1981-02-17 | Gaf Corporation | Fungicidal process using 1-(alkoxyaroyl)guanidines |
WO1994026709A1 (en) | 1993-05-17 | 1994-11-24 | Fujisawa Pharmaceutical Co., Ltd. | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS |
DE4421536A1 (en) | 1994-06-20 | 1995-12-21 | Hoechst Ag | Phenyl-substituted alkenylcarboxylic acid guanidines bearing perfluoroalkyl groups, processes for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them |
JPH08225513A (en) | 1994-12-21 | 1996-09-03 | Kanebo Ltd | Naphthoylguanidine derivative |
EP0744397A2 (en) | 1995-05-22 | 1996-11-27 | Hoechst Aktiengesellschaft | Fluorophenyl substituted alkenyl carboxylic acid guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agent as well as a medicament containing them |
EP0810206A1 (en) | 1996-05-29 | 1997-12-03 | Hoechst Aktiengesellschaft | Substituted 2-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicament containing them |
WO2004112687A2 (en) * | 2003-06-26 | 2004-12-29 | Biotron Limited | Antiviral acylguanidine compounds and methods |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2734904A (en) | 1956-02-14 | Xcxnhxc-nh | ||
US4544670A (en) * | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
JPH0218632A (en) | 1988-07-07 | 1990-01-22 | Matsushita Electric Ind Co Ltd | Method and device for evaluation of logical gate |
DE3929582A1 (en) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINE AND THE MEDICINE CONTAINING IT |
DE4328869A1 (en) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
DE19527305A1 (en) | 1995-07-26 | 1997-01-30 | Hoechst Ag | Substituted cinnamic acid guanidides, process for their preparation, their use as a medicament or diagnostic agent and medicament containing them |
DE19606355A1 (en) * | 1996-02-12 | 1997-08-14 | Schering Ag | Contraceptive release systems with antiviral and / or antibacterial effects |
AUPO545297A0 (en) * | 1997-03-04 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
US20030113352A1 (en) * | 2001-12-14 | 2003-06-19 | The Regents Of The University Of California | Neutralization of stratum corneum to treat hyperkeratotic skin lesions |
WO2004056181A1 (en) * | 2002-12-23 | 2004-07-08 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery (2) |
WO2004087138A1 (en) * | 2003-03-31 | 2004-10-14 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
US20070099968A1 (en) | 2004-06-26 | 2007-05-03 | Biotron Limited | Antiviral compounds and methods |
DK1902017T3 (en) * | 2005-06-24 | 2014-06-30 | Biotron Ltd | Antiviral acylguanidine compounds |
WO2007045572A1 (en) * | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors |
JP5727842B2 (en) | 2011-04-12 | 2015-06-03 | 日野自動車株式会社 | Instrument panel structure of vehicle |
KR101331921B1 (en) * | 2013-01-16 | 2013-11-21 | 에스케이플래닛 주식회사 | Apparatus and method for providing interaction service for safety of kids |
-
2006
- 2006-06-23 DK DK06741271.8T patent/DK1902017T3/en active
- 2006-06-23 PL PL06741271T patent/PL1902017T3/en unknown
- 2006-06-23 ES ES06741271.8T patent/ES2491217T3/en active Active
- 2006-06-23 DK DK13197255.6T patent/DK2826770T3/en active
- 2006-06-23 CN CN201310097430.5A patent/CN103274970B/en active Active
- 2006-06-23 US US11/922,281 patent/US8669280B2/en active Active
- 2006-06-23 EP EP06741271.8A patent/EP1902017B1/en active Active
- 2006-06-23 WO PCT/AU2006/000880 patent/WO2006135978A1/en active Application Filing
- 2006-06-23 BR BRPI0612309A patent/BRPI0612309B8/en active IP Right Grant
- 2006-06-23 CN CN2006800226410A patent/CN101208297B/en active Active
- 2006-06-23 BR BR122020006906A patent/BR122020006906B8/en active IP Right Grant
- 2006-06-23 JP JP2008517277A patent/JP5373392B2/en active Active
- 2006-06-23 SG SG201004454-3A patent/SG163517A1/en unknown
- 2006-06-23 AU AU2006261593A patent/AU2006261593B2/en active Active
- 2006-06-23 NZ NZ596107A patent/NZ596107A/en unknown
- 2006-06-23 NZ NZ564398A patent/NZ564398A/en unknown
- 2006-06-23 PL PL13197255T patent/PL2826770T3/en unknown
- 2006-06-23 ES ES13197255T patent/ES2710662T3/en active Active
- 2006-06-23 KR KR1020147010199A patent/KR20140072101A/en active Search and Examination
- 2006-06-23 KR KR1020087001886A patent/KR101419327B1/en active IP Right Grant
- 2006-06-23 PT PT13197255T patent/PT2826770T/en unknown
- 2006-06-23 CA CA2612403A patent/CA2612403C/en active Active
- 2006-06-23 PT PT67412718T patent/PT1902017E/en unknown
- 2006-06-23 NZ NZ610715A patent/NZ610715A/en unknown
- 2006-06-23 EP EP13197255.6A patent/EP2826770B1/en active Active
- 2006-06-23 ZA ZA200800256A patent/ZA200800256B/en unknown
-
2008
- 2008-04-17 HK HK08104365.1A patent/HK1109615A1/en unknown
-
2012
- 2012-09-24 JP JP2012209126A patent/JP5616410B2/en active Active
-
2013
- 2013-11-05 US US14/071,870 patent/US9440926B2/en active Active
-
2015
- 2015-07-20 HK HK15106877.8A patent/HK1206330A1/en unknown
-
2016
- 2016-09-12 US US15/262,075 patent/US10683263B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4251545A (en) | 1979-09-19 | 1981-02-17 | Gaf Corporation | Fungicidal process using 1-(alkoxyaroyl)guanidines |
WO1994026709A1 (en) | 1993-05-17 | 1994-11-24 | Fujisawa Pharmaceutical Co., Ltd. | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS |
DE4421536A1 (en) | 1994-06-20 | 1995-12-21 | Hoechst Ag | Phenyl-substituted alkenylcarboxylic acid guanidines bearing perfluoroalkyl groups, processes for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them |
JPH08225513A (en) | 1994-12-21 | 1996-09-03 | Kanebo Ltd | Naphthoylguanidine derivative |
EP0744397A2 (en) | 1995-05-22 | 1996-11-27 | Hoechst Aktiengesellschaft | Fluorophenyl substituted alkenyl carboxylic acid guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agent as well as a medicament containing them |
EP0810206A1 (en) | 1996-05-29 | 1997-12-03 | Hoechst Aktiengesellschaft | Substituted 2-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicament containing them |
WO2004112687A2 (en) * | 2003-06-26 | 2004-12-29 | Biotron Limited | Antiviral acylguanidine compounds and methods |
Non-Patent Citations (8)
Title |
---|
ARZNEIMITTEL-FORSCHUNG, vol. 25, no. 10, 1975, pages 1477 - 1482 |
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 45, no. 8, 1997, pages 1282 - 1286 |
DATABASE CA [online] BREAM J.B. ET AL., XP003006288, accession no. STN Database accession no. (84:12322) * |
DATABASE CA [online] YAMAMOTO T. ET AL., XP003006287, accession no. STN Database accession no. (127:257127) * |
DATABASE WPI Week 198110, Derwent World Patents Index; Class C03, AN 1981-17328D, XP003006289 * |
DATABASE WPI Week 199605, Derwent World Patents Index; Class B05, AN 1996-041051, XP003006291 * |
DATABASE WPI Week 199645, Derwent World Patents Index; Class B05, AN 1996-450947, XP003006290 * |
See also references of EP1902017A4 |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518960B2 (en) | 2007-05-23 | 2013-08-27 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
US9353051B2 (en) | 2007-05-23 | 2016-05-31 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
WO2008147962A1 (en) * | 2007-05-23 | 2008-12-04 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
KR101558403B1 (en) * | 2007-08-03 | 2015-10-07 | 바이오트론 리미티드 | Hepatitis c antiviral compositions and methods |
WO2009018609A1 (en) * | 2007-08-03 | 2009-02-12 | Biotrom Limited | Hepatitis c antiviral compositions and methods |
AU2013219202B2 (en) * | 2007-08-03 | 2016-12-08 | Biotron Limited | Hepatitis C antiviral compositions and methods |
CN101827589B (en) * | 2007-08-03 | 2016-08-17 | 拜伊特朗有限公司 | The compositions of anti-hepatitis c virus and method |
JP2010535154A (en) * | 2007-08-03 | 2010-11-18 | バイオトロン リミテッド | Hepatitis C antiviral composition and method |
AU2008286240B2 (en) * | 2007-08-03 | 2013-05-23 | Biotron Limited | Hepatitis C antiviral compositions and methods |
EP2659885A1 (en) * | 2007-08-03 | 2013-11-06 | Biotron Limited | Hepatitis C Antiviral Compositions and Methods |
EP2394988A4 (en) * | 2009-02-09 | 2012-09-05 | Astellas Pharma Inc | Substituted acylguanidine derivative |
EP2394987A1 (en) * | 2009-02-09 | 2011-12-14 | Astellas Pharma Inc. | Acylguanidine derivative |
EP2394987A4 (en) * | 2009-02-09 | 2012-09-05 | Astellas Pharma Inc | Acylguanidine derivative |
EP2394988A1 (en) * | 2009-02-09 | 2011-12-14 | Astellas Pharma Inc. | Substituted acylguanidine derivative |
WO2011016504A1 (en) | 2009-08-06 | 2011-02-10 | アステラス製薬株式会社 | Nitrogenous-ring acylguanidine derivative |
US8853242B2 (en) | 2009-08-06 | 2014-10-07 | Astellas Pharma Inc. | Nitrogenous-ring acylguanidine derivative |
US11492353B2 (en) | 2010-07-22 | 2022-11-08 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
US11344565B2 (en) | 2014-10-29 | 2022-05-31 | Gilead Sciences, Inc. | Methods for the preparation of ribosides |
US11266666B2 (en) | 2014-10-29 | 2022-03-08 | Gilead Sciences, Inc. | Methods for treating Filoviridae virus infections |
US11007208B2 (en) | 2015-09-16 | 2021-05-18 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
US11382926B2 (en) | 2015-09-16 | 2022-07-12 | Gilead Sciences, Inc. | Methods for treating Arenaviridae and Coronaviridae virus infections |
US11260070B2 (en) | 2017-03-14 | 2022-03-01 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
US11597742B2 (en) | 2017-05-01 | 2023-03-07 | Gilead Sciences, Inc. | Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate |
US11266681B2 (en) | 2017-07-11 | 2022-03-08 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
US11975017B2 (en) | 2017-07-11 | 2024-05-07 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
WO2021102508A1 (en) * | 2019-11-26 | 2021-06-03 | Biotron Limited | Methods of treating hiv-1 infection |
WO2021154687A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
US11701372B2 (en) | 2020-04-06 | 2023-07-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs |
US11491169B2 (en) | 2020-05-29 | 2022-11-08 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11975012B2 (en) | 2020-05-29 | 2024-05-07 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11903953B2 (en) | 2020-05-29 | 2024-02-20 | Gilead Sciences, Inc. | Remdesivir treatment methods |
WO2021262826A2 (en) | 2020-06-24 | 2021-12-30 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
WO2022046631A1 (en) | 2020-08-24 | 2022-03-03 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11814406B2 (en) | 2020-08-27 | 2023-11-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2022081973A1 (en) | 2020-10-16 | 2022-04-21 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
WO2022251318A1 (en) | 2021-05-26 | 2022-12-01 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
WO2023092180A1 (en) * | 2021-11-24 | 2023-06-01 | Biotron Limited | Methods of treating sars-cov-2 infection |
US11845755B2 (en) | 2022-03-02 | 2023-12-19 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11851438B2 (en) | 2022-03-02 | 2023-12-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and methods for treatment of viral infections |
US11780844B2 (en) | 2022-03-02 | 2023-10-10 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023167938A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023168194A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
WO2023168254A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
WO2023239665A1 (en) | 2022-06-06 | 2023-12-14 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
WO2024006461A1 (en) | 2022-06-30 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006261593B2 (en) | Antiviral compounds and methods | |
JP3563106B2 (en) | Substituted benzoylguanidines, their preparation and preparations containing them | |
CA2695390C (en) | Hepatitis c antiviral compositions and methods | |
KR100368513B1 (en) | Phenyl-substituted alkenylcarboanides having perfluoroalkyl groups, methods for their preparation and pharmaceutical compositions containing them | |
JP3718250B2 (en) | Phenyl-substituted alkylcarboguanides having perfluoroalkyl groups and methods for their preparation | |
RU2160727C2 (en) | Benzoylguanidines, method of preparation thereof, intermediates for their preparation, inhibition method, and drug | |
AU2013205388B2 (en) | Antiviral compounds and methods | |
JPH09169721A (en) | Sulfonylamino-substituted benzoylguanidine compound, its production, its use as medicine or diagnostic auxiliary, and medicine containing it | |
RU2212400C2 (en) | Ortho-substituted benzoylguanidines and medicinal agents containing thereof | |
JPH09227496A (en) | Ortho-substituted benzoylguanidines, their production, use as medicine or diagnostic agent and medicine containing the same | |
EP2265117A1 (en) | Inhibitors of protein phosphatase-1 and uses thereof | |
AU2013219202A1 (en) | Hepatitis C antiviral compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11922281 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2612403 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 564398 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006261593 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008517277 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006741271 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680022641.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 290/KOLNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006261593 Country of ref document: AU Date of ref document: 20060623 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087001886 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006261593 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006741271 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0612309 Country of ref document: BR Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147010199 Country of ref document: KR |